Glioblastoma : the effects of the dual kinase inhibitor PI-103 on glioblastoma cells

Abstract

Glioblastoma is the most common primary brain tumour in adults. Under the current first-line therapy with surgical resection as well as radiotherapy and concomitant or adjuvant chemotherapy, the median survival rate is only about 16 months, so that new therapies are urgently needed. In 88% of all glioblastoma patients, changes in the PI3K signalling pathway are found. Therefore in this study the influence of the inhibition of the PI3K signalling pathway on glioblastoma cells was investigated using the dual kinase inhibitor PI-103. It was shown that inhibition of the PI3K pathway can successfully inhibit the proliferation of both differentiated cells and stem cells. Furthermore, the migration of differentiated cells can be significantly reduced. Unfortunately, however, no effect on the apoptosis of the cells could be achieved and a sensitization to apoptosis triggered by chemotherapy was not possible.